Authors
Latest:
Evaluating the Activity of Trabectedin and Radiotherapy in SarcomaAlessandro Gronchi, MD, discusses a phase 2 trial of trabectedin and radiotherapy in patients with soft-tissue sarcoma.
Latest:
From the Editor: PARP Inhibitors, Biomarker Research, and Gene EditingOur physician editor-in-chief highlights the February 2015 issue of The Journal of Targeted Therapies in Cancer.
Latest:
A Study of Brentuximab Vedotin and Nivolumab in Relapsed or Treatment-Resistant Hodgkin LymphomaAlex Herrera, MD, assistant professor, City of Hope, discusses a study investigating the use of brentuximab vedotin (Adcetris) and nivolumab (Opdivo) in the treatment of relapsed or treatment-resistant Hodgkin lymphoma during the American Society of Hematology (ASH) Annual Meeting.
Latest:
Phase II Trial Shows Antitumor Activity With Cemiplimab in mCSCCAlexander D. Guminski, MD, PhD, discusses the 12-month follow-up data from a phase II study investigating the role of cemiplimab as a treatment for patients with metastatic cutaneous squamous cell carcinoma.
Latest:
Drilon Explains Testing for NTRK Gene FusionsAlexander Drilon, MD, discusses what to know when testing for NTRK gene fusions in patients with lung cancer.
Latest:
Testing for NTRK Gene Fusions in the Community SettingAlexander Drilon, MD, discusses what community oncologists should know about testing for NTRK gene fusions in patients with solid tumors.
Latest:
Highlighting Latest Additions to the Treatment Landscape for AMLAlexander E. Perl, MD, discusses the latest advancements in the treatment landscape for patients with acute myeloid leukemia. These advances are driven by 2 factors: a better understanding of the biology of the disease and improving therapeutics to meet that understanding.
Latest:
HHLA2 Vs PD-L1 Expression in Urothelial TumorsAlexander I. Sankin, MD, assistant professor of Urology at Montefiore Medical Center at the Albert Einstein College of Medicine, discusses the differences between the recently defined checkpoint HHLA2 and PD-L1 expression in urothelial tumors, as well as next steps in this space.
Latest:
Dr. Alexander Kutikov on Options Afforded to Kidney Cancer PatientsKutikov points out that not every mass needs to be resected and that patients need to understand the risks associated with each decision they make in the treatment process.
Latest:
3-Year Update Shows Continued Efficacy of Pembrolizumab for MelanomaAlexander M. Eggermont, MD, PhD, discusses the results of the KEYNOTE 054 trial of pembrolizumab versus placebo in patients with high-risk stage III melanoma after a complete resection.
Latest:
Results of Pembrolizumab in High-Risk Stage III MelanomaAlexander M. M. Eggermont, MD, PhD, director general of Gustave Roussy Cancer Campus Grand Paris in Villejuif, France, discusses the phase III results from the EORTC 1325-MG/KEYNOTE-054 trial presented at the 2018 AACR Annual Meeting.
Latest:
Challenges to Overcome With CAR T-Cell Therapy for Acute Myeloid LeukemiaAlexander Perl, MD, an associate professor of medicine at the University of Pennsylvania, discusses the current challenges with CAR T-cell therapy for the treatment of patients with acute myeloid leukemia
Latest:
Intra-Arterial Therapies for Hepatic MalignanciesThe researchers review intra-arterial therapies and the latest literature supporting their use, categorized by different tumor types.
Latest:
Efficacy of Onapristone in PR-Expressing TumorsAlexander Zukiwski, MD, CEO, Arno Therapeutics, Inc., discusses the efficacy of onapristone (ONA) in progesterone receptor (PR)-expressing tumors.
Latest:
Second-Line Immunotherapy Combos in MORPHEUS Trial for Advanced Urothelial CarcinomaAlexandra Drakaki, MD, assistant professor of medicine, hematology, and oncology, University of California, Los Angeles, discusses the goals of the phase Ib/II MORPHEUS trial, which is an umbrella study evaluating several second-line immunotherapy combinations in patients with advanced or metastatic urothelial carcinoma.
Latest:
The Promise of Olaparib for the Treatment of HER2-Negative Breast CancerAlexandra S. Zimmer, MD, staff clinician, Women's Malignancies Branch, National Cancer Institute Center for Cancer Research, discusses the promising data seen thus far with olaparib (Lynparza) for the treatment of HER2-negative breast cancer.
Latest:
The Importance of the Approval of Lanreotide and its Known Side EffectsAlexandria Phan, MD, discusses the importance of the approval of lanreotide for unresectable, well or moderately differentiated, locally advanced or metastatic GEP-NETs.
Latest:
Questions Remain When Treating Patients With CLLAlexey Danilov, MD, PhD, explains the unmet needs for patients with relapsed/refractory chronic lymphocytic leukemia.
Latest:
Patterns of Response and Resistance Among Hematologic MalignanciesAlfred L. Garfall, MD, MS, assistant professor of Medicine, the Hospital of the University of Pennsylvania, discusses patterns of response and resistance among hematologic malignancies.
Latest:
Immune Checkpoint Inhibitors in CRCAli Maawy, MD, and Patrick M. Boland, MD, provide a brief review of the immune environment of colorectal cancer (CRC) and recently reported studies of immunotherapy in CRC.
Latest:
The Importance of the ACCC's Focus on Compensation With Ali McBride as PresidentAli McBride, PharmD, MS, BCOP, discussed during the recent National Oncology Conference his goals for ACCC while serving as president, which include focusing on education, innovation, and compensation.<br />
Latest:
Metastatic Hormone-Sensitive Prostate Cancer Should Include Docetaxel Alongside ADTTreatment initiation for hormone-sensitive metastatic prostate cancer should include the addition of docetaxel to androgen deprivation therapy (ADT) as standard of care.
Latest:
Efficacy Results for Lorlatinib in Patients With ALK-Positive NSCLCAlice Shaw, MD, PhD, director of Thoracic Oncology at Massachusetts General Hospital, discussed the efficacy results from a recent trial investigating lorlatinib as treatment for patients with anaplastic lymphoma kinase-positive (ALK) non–small cell lung cancer that had failed other treatments prior, including crizotinib (Xalkori) and other multiple ALK tyrosine-kinase inhibitors.
Latest:
Phase III Results for Alectinib Compared With Crizotinib in ALK+ Metastatic NSCLCAlice T. Shaw, MD, PhD, director, thoracic oncology, Massachusetts General Hospital, discusses results of the phase III clinical trial comparing alectinib (Alecensa) versus crizotinib (Xalkori) in first-line treatment for ALK-positive, advanced non–small cell lung cancer.
Latest:
First Real-World Data on Second-Generation AR Inhibitor Use in nmCRPCA review of real-world data from the DEAR study of darolutamide, enzalutamide and apalutamide for the treatment of nonmetastatic castration-resistant prostate cancer is given by Alicia Morgans, MD, MPH.
Latest:
Study Finds Link Between E-Cigarette Use and Bladder CancerFindings from a recent pilot study done at the University of Pittsburgh Medical Center showed a potential link between e-cigarette use and bladder cancer.
Latest:
Concomitant Chemoradiotherapy Demonstrates Survival Benefit in Nasopharyngeal CarcinomaThe addition of chemotherapy, either adjuvant or induction, to concomitant chemoradiotherapy (CRT) achieved a significantly high survival benefit for patients with locally advanced nasopharyngeal carcinoma.
